Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Vir Biotechnology Inc VIR

Healthcare Biotechnology
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:VIR)

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Business Wire 3 days ago

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

Business Wire 4 days ago

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

Business Wire 7 days ago

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Business Wire October 31, 2024

Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024

Business Wire October 17, 2024

Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD's The Liver Meeting® 2024

Business Wire October 15, 2024

Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Business Wire October 3, 2024

Vir Biotechnology Appoints Jason O'Byrne as Chief Financial Officer

Business Wire September 10, 2024

Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

Business Wire September 9, 2024
View More News ››

Opinion & Analysis (NDAQ:VIR)

Vir Partners with Samsung Biologics on Large-Scale Manufacture of COVID-19 Antibody Treatment

Streetwise Reports April 13, 2020

Vir Biotech Shares Rise on Joint Research Efforts with the NIH to Combat Coronaviruses

Streetwise Reports March 12, 2020
View More Opinion ››

Bullboard Posts (NDAQ:VIR)

Tobevibart Monotherapy and Combination Therapy with Elebsira

News; $VIR Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in...
whytestocks - June 5, 2024

Vir Biotechnology Announces SOLSTICE Data to be Featured as

Just In: $VIR Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study...
whytestocks - May 21, 2024

RE:The only pill against Omicron?

Oops: The name of the pill is "Sotromivab". It is commercialized by GSK "GlaxoSmithKline"
emiltech - January 11, 2022

The only pill against Omicron?

Looks like it is in a sweet spot. Available only for immuno-depressed patients for now. Hope it could be available to the general cohorts...
emiltech - January 11, 2022

$iMIN making moves in Ethereum Crypto !! 🚀🚀🚀🚀🚀

iMining Launches Fractional Staking to Enable Retail Investors to Participate in Ethereum 2.0's Proof-Of-Stake Mining Vancouver...
Saaaa1 - May 6, 2021
View more Bullboard ››

Alphamin Resources Corp.

Alphamin Resources Corp.

Alphamin Resources Corp. is a Mauritius-based company, which is engaged in the production and sale of tin concentrate from ...
View More »